Synairgen plc (LON:SNG – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 5.06 ($0.07) and traded as low as GBX 3.55 ($0.05). Synairgen shares last traded at GBX 4.01 ($0.05), with a volume of 1,265,634 shares changing hands.
Synairgen Stock Performance
The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of £8.07 million, a PE ratio of -133.50 and a beta of -2.23. The firm’s fifty day moving average price is GBX 3.81 and its 200 day moving average price is GBX 5.06.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Synairgen
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Use the MarketBeat Excel Dividend Calculator
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Why Are These Companies Considered Blue Chips?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
